Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 18, Number 3—March 2012

Letter

Adherence to Oseltamivir Guidelines during Influenza Pandemic, the Netherlands

Esther H. Fietjé, Daphne PhilbertComments to Author , Erica C.G. van Geffen, Nina A. Winters, and Marcel L. Bouvy
Author affiliations: Author affiliation: Utrecht University, Utrecht, the Netherlands

Main Article

Table

Reported risk factors of patients with and without influenza symptoms who were dispensed a prescription for oseltamivir, the Netherlands, 2009–10

Risk factor No. (%) patients*
Total, n = 300 Influenza symptoms, n = 223 No influenza symptoms, n = 77
Chronic condition 211 (70.3) 154 (69.1) 57 (74.0)
Chronic respiratory disease 127 (42.3) 98 (43.9) 29 (37.7)
Lower immune resistance caused by illness or medical treatment 76 (25.3) 50 (22.4) 26 (33.8)
Cardiovascular disease 52 (17.3) 34 (15.2) 18 (23.4)
Diabetes 44 (14.7) 28 (12.6) 16 (20.8)
Renal disease 10 (3.3) 5 (2.2) 5 (6.5)
Other 125 (41.7) 86 (38.6) 39 (50.6)
Age >60 y 66 (22.0) 35 (15.7) 31 (40.3)
Age <2 y 36 (12.0) 35 (15.7) 1 (1.3)
Regular patient contact by health care worker 22 (7.3) 15 (6.7) 7 (9.1)
Pregnancy 5 (1.7) 2 (0.9) 3 (3.9)
No. risk factors
0 44 (14.7) 34 (15.2) 10 (13.0)
1 137 (45.7) 111 (49.8) 26 (33.8)
2 72 (24.0) 53 (23.8) 19 (24.7)
>3 47 (15.7) 25 (11.2) 22 (28.6)

*Percentages may total >100% because of rounding.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO